This is the authors' abstract. We don't add key points for this paper.
Altered complement component 3 (C3) activation in patients with alpha-1 antitrypsin (AAT) deficiency (AATD) has been reported. To understand the potential impact on course of inflammation, the aim of this study was to investigate whether C3d, a cleavage-product of C3, triggers interleukin (IL)-1β secretion via activation of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome. The objective was to explore the effect of AAT augmentation therapy in patients with AATD on the C3d/complement receptor 3 (CR3) signalling axis of monocytes and on circulating pro-inflammatory markers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gogoi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: